PerkinElmer has released four new ready-to-use AlphaLisa KRAS kits aimed at helping cancer researchers identify potential new therapeutic candidates for a wide range of prevalent cancers.
Designed to help researchers better understand KRAS protein structures and mutations, the kits all come with recombinant proteins, detection reagents, and assay buffers, according to the company.
KRAS is a prime drug target, as the KRAS mutation is found in approximately 25% of cancers, making it one of the most common gene mutations linked to cancer; the mutation can be found in different cancers from lung to colorectal to pancreatic cancers.
The validated kits can identify KRAS inhibitors in a no-wash format without any need for optimization, PerkinElmer said.
